1. Is there an acceptable method for early detection of prostate cancer available on a population basis? 2. Do the current results provide encouragement for proceeding to develop widespread, randomized tri als? 3. What is the proper way to conduct such efforts and what other important issues should be considered? 4. What are the bases for the treatment of patients with prostate cancer w hen discovered?
These issues are addressed in a comprehensive fashion below.
EPIDEMIOLOGY WORKGROUP
In many countries of the world, prostate cancer is the second most common form of cancer in men and in the United States it has recently overtaken lung cancer in terms of absolute incidence, although it remains second to lung cancer as a cause of death. Given that in several countries, a higher number of children born after 1945 will be in their mid-fifties in the early part of the 21st century (at which age cancer risk becomes an important consideration), coupled with the trend toward in creased life expectancy, there will be an increase in the numbers of patients diagnosed with prostate cancer even if incidence rates remain fixed at 1980 levels. In the absence of treatment improvements, and with pros pects for prevention by lifestyle modification only a re mote hope in the current circumstances, it seems that there will also be an increase in the number of deaths from prostate cancer worldwide.
The situation could be further augmented by the presence of temporal trend toward increased risk of prostate cancer that is consistently reported in many countries and that is unlikely to be entirely artifact. However, in many countries there has been little change in the mortality rate for prostate cancer, partic ularly at younger (< 70 years) ages since 1950 (Boyle P, Evstifeeva T, Maisonneuve P, Macfarlane EJ, Pagano F, unpublished data).
A major effort is required to reduce the impact of these changes and reduction of mortality by population screening has emerged as one possible way to accom plish this.1 In this context, screening involves the exam ination of asymptomatic men to classify them as likely or unlikely to have prostate cancer. Men who appear likely to have the disease are investigated further to ar rive at a final diagnosis and those who are found to have the disease are treated. Screening calls attention to the likelihood of disease before symptoms appear. The goal of a screening program is to reduce mortality from the disease among those screened by treatment of disease before symptoms appear. There have been criteria es tablished to determine whether a screening activity could be justified in a particular circumstance2 and at the present time, these criteria are almost completely fulfilled for prostate cancer. 3 The notable exceptions are the lack of detailed knowledge of the natural history of prostate cancer and lack of direct evidence that screen ing with the currently available modalities can lead to a reduction in prostate cancer mortality.
Although population screening for prostate cancer cannot be recommended as public health policy at the present time, there are strong arguments supporting the conduct of trials of screening (see Appendix 1 for this and other recommendations of this workgroup). It is recognized that possibilities for the conduct of such ran domized trials are favorable in Europe at the present time. Such randomized trials need to be large and of long duration. They will be more complicated than trials of mammography and breast cancer screening as a re sult of several factors, including the nature of prostate cancer. In particular, there is a need to have reliable in formation about patterns of cancer care and treatment of prostate cancer in the study region, Men in an age group that is not treated according to local policy (older than 70 years of age in some areas) should not be re cruited into screening trials as they are very unlikely to benefit from participation. Information is required about patterns of care in the study region. Patterns of health care for men enrolled in screening trials should be as similar as possible in both the screened and the unscreened group members. Cancer registries in the study region have an important role in identifying any interval cancers arising in the study participants, some of which may be missed, and in providing a backup to existing follow-up procedures. Cancer registries also provide an important resource of information regarding background incidence, mortality, and survival rates and follow-up for men who either refuse to participate in the trial or drop out during the study.
Care is required when dealing with aspects of the diagnosis of prostate cancer. A potential problem in volves autopsy diagnosis, but this is only a relevant finding when it identifies the prostate as the primary site in the case of a man who died of metastatic disease whose primary origin was unknown (or wrongly attrib uted to another site) in life (occult cancer). In each trial, a committee should be established to determine whether prostate cancer was the underlying cause of death in study participants. Although death certificates appear to be reasonably reliable, there is need for de tailed examination of each cause of death by clinicians who are expert in the disease in question. The need for large trials argues strongly for multicentred studies that probably will need to be conducted in international populations. Careful scrutiny of the reproducibility of the determination of prostate cancer as underlying cause of death in different countries is needed.
Screening trials require careful planning to ensure that the data can be used correctly for evaluation. The most reliable evaluation of screening activities is through the correct analysis of the randomized clinical trial data. However, modeling strategies have also proved useful and have a role in helping choose be tween the utility of different screening procedures. 4 The list of data required from a screening trial to allow eval uation is contained in Appendix 2.
As stated above, the goal of screening is to decrease the death rate from prostate cancer. Using death as the principle endpoint minimizes many possible biases and requires 10-20 years to complete. Regardless of the screening tests employed, the present climate of tech nologic advances offers the option of obtaining inter mediate results in a shortened time by using prognostic indicators of death from prostate cancer. A decrease in the incidence rate of advanced cancer is the best inter mediate indicator of a ultimate reduction in mortality. The use of intermediate endpoints at this time must be informal because they themselves require validation by mortality data from screening trials;5 valid intermediate endpoints classify tumors into a number of categories within which survival is independent of mode of detec tion.
Using data from the Surveillance, Epidemiology, and End Results Program, available prognostic death indicators were ranked by their death potential with 7 to 18 years of follow-up. Gleason grade was found to be a strong indicator of the virulence of cancers in all stages and should also attempt to be gathered on all cancers.6 There should be a uniform method of record ing staging information on prostate cancer that is used in all countries and can be compared through time (TNM is the most widely used scheme internationally).
Quality of life is a major issue, particularly when considering disease in older men. The criteria estab lished by Wilson and Jungner, however, lack any crite rion about quality of life. It is recommended that two important aspects of quality of life be measured in study participants: general quality of life and quality of urologic life, the latter, for example, including urinary symptomatology, annoyance of symptoms, interfer ence with daily living, and sexual function. Quality of life assessment should be performed both for men free from prostate cancer and men with the disease in the screened and control groups. The measurements should be made at several stages of the disease course and also during eventual life-years gained. Much basic research work remains to be performed in this field before vali dated instruments will be available for use.
In conducting large scale screening trials, it is im portant to maximize the utility of this resource, for ex ample by conducting etiologic studies within this as sembled cohort. The establishment of a biologic data bank would maximize the value of this resource and help provide answers to several important research questions about prostate cancer that are complementary to the main question addressed by screening trials.
The potential list of data items is extremely long; this list represents the minimum data required for a thorough examination of the findings from screening trials. ). There should be a liaison between study coordinators and cancer tumor registries that is active in the re gion where screening trials are being conducted. The principal method of evaluating screening trials is a correct statistical analysis of randomized trial data, but modeling is also of importance to help in the comparison of the utility and cost-effectiveness of different screening strategies. Each study requires the establishment of a committee to evaluate the cause of death of study participants. There is a need for more research about the compa rability of cause of death abstraction in different countries. Using death from prostate cancer as the principle end point in screening trials minimizes several possible biases but requires 10 to 20 years to complete. In termediate results could be obtained by using prog nostic indicators of death from prostate cancer (e.g., grading, stage, etc.).
Appendix 1

Recommendations of the Epidemiologic
Appendix 2
Minimal Information Required for Evaluation of Cancer Screening Trials
Target population Invited population Attendance
PATHOLOGY WORKGROUP
The Pathology Working Group (PWG) recognizes that screening programs have the authority and responsibil ity to specify conditions of quality control and quality assurance within the screening facility. However, once an abnormality is detected, the follow-up facilities for surgical excision and pathologic examination are not necessarily a part of the screening facility. Therefore, the PWG's objective was to develop criteria for the ex amination of prostate tissue specimens that would be generally acceptable to practicing surgical pathologists for the formulation of their consultation reports. The information included below is directed primarily to the consultative practice of pathology and is not specifically for research. Nevertheless, this information may be used in a clinical trial setting, and can be modified as appropriate for use in a specific protocol or institution. In this context, the participants of the PWG have for mulated the following recommendations for the exami nation and surgical pathology consultation reports of prostate cancer specimens to document the extent of tis sue removed, validate the diagnosis of cancer in the specimen (or its absence), and provide information that may be used for International Union Against Cancer/ American Joint Committee on Cancer pTNM classifi cation and staging, selection of therapy, and estimation of prognosis, The PWG therefore has included much of the data that have already been developed and reality tested by the Cancer Committee of the College of Amer ican Pathologists,1
The PWG made some general observations during the development of these recommendations. They unanimously agreed that prostate carcinomas should be assigned a histologic grade, and preferred a three-grade system; however, they also concurred that the grading system employed by a pathologist should be deter mined by her/his local medical practice environment. Therefore, the PWG include the following in the rec ommendation for histologic grading: "Any grading sys tem as desired, such as Gleason's score"1 (see below). Of course, the grading system used should include a verbal definition in the report such as . .moderately differentiated, grade 2."
The surgical pathology consultation report of a prostate specimen should include a statement confirm ing the presence (or absence) of carcinoma, or that it may not be possible to make a definitive diagnostic evaluation for carcinoma and state the reason (e.g., pos sibly due to limitations of the specimen). Prostate can cer associated lesions, such as prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH), and the effects of therapy, may also be included. The PWG recommends that a group of pathologists de velop a lexicon of definitions of terms, with appropriate related photomicrographs, to assist pathologists in the uniform application of the terminology specified in this report.
Recommendations follow for the information to be included in the surgical pathology consultation reports for four categories of specimens (1) needle biopsy, (2) transurethral resection of prostate (TURP), (3) supra pubic or retropubic prostate enucleation (subtotal pros tatectomy), and (4) radical prostatectomy. Although prostate carcinoma can be diagnosed by fine needle as piration cytology of the prostate gland with or without DNA analysis by flow cytometry or nuclear morphome try, this report is limited to solid tissue examination. There is repetition of information in the four categories of specimens because many of the data are common for all types of specimens; this deliberate repetition is in tended for the convenience of the reader and for those who may wish to duplicate this material for use in their laboratory.
We cannot emphasize too strongly how important it is to provide basic clinical data to the pathologist for appropriate patient identification and clinical-patho logic correlation. undertaken by a trained health care professional, the positive predictive value can be 25-50%.1 Experience from Sweden indicated that it may be feasible to train nonphysicians to evaluate the prostate sensitively and effectively, but it was agreed that such a practice may be unacceptable in certain cultures. It was agreed that universal training of medical students to carry out DRE should be a goal of medical education. However, it must not be forgotten that the finer interpretation of the re sults of DRE is best undertaken by a trained urologist, even though it is accepted that DRE is a subjective pro cess that has limited value for diagnosis and staging, DRE, as a simple procedure, is inadequate for diagnosis and screening and inaccurate for staging.2,3
Recommendations for Data to be Included in the Surgical Pathology Consultation Report for the Four Types of Specimens
Tumor Markers
Prostate Acid Phosphatase
It was agreed that prostate acid phosphatase may have limited use in staging but not in diagnosis or screening. An elevated PAP is indicative of local or metastatic spread of prostate cancer and usually indicates noncurable disease,4
Prostate Specific Antigen
It was agreed that PSA is the most appropriate tumor marker to screen for prostate cancer but has limited ac curacy in staging.5-7 There was no argument about the absolute upper value of normality (4 ng/m l mono clonal); in Europe, prostate volume is considered to be important, but it was agreed that this is an important priority for the future. Data were presented that indi cated that PSA generally is proportional to prostate (and tumor) volume, and that a PSA greater than 6 n g / ml is more commonly associated with a tumor volume that may not be curable. because the intent is to impact only those tumors that are biologically significant. Data were presented indi cating that tumors detected with a serum PSA of 4-10 ng/m l are associated with a 30-50% incidence of cap sular involvement and up to 10% incidence of seminal vesicle involvement (Fig. 2) .10,11 All accepted that longi tudinal PSA measurements are very promising for fu ture study in screening, particularly w hen PSA is less than 10 ng/m l. Quality assurance of PSA assay is crucial for screen ing programs and it was agreed that this should be per formed in Central Reference Laboratories. Also, PSA has a practical advantage over PAP in that it is stable at room temperature and therefore is suitable for batch processing and off-site collection (Dr. A. Lijia, personal communication). Caution was urged for some instances of mildly elevated PSA that increase due to infection 1196 CANCER March 1, 1995r (prostatitis) and a consideration should be made for trial of antibiotics.
Transrectal Ultrasound
Transrectal ultrasound of the prostate is now generally reserved for the evaluation of abnormal DRE or PSA elevated beyond 4.0 ng/m l.12"14 This helps select for higher risk patients and increases the predictive value for transrectal ultrasound abnormalities. Transrectal ul trasound appearance of prostate cancer follows the gen eral morphologic breakdown of: 30% nodular, 50% nodular and infiltrative and 20% infiltrative. 15 This cor responds to a spectrum of very hypoechoic to isoechoic appearance, respectively. Both the anterior and poste rior periphery of the prostate should be searched care fully for lesions 6 m m -2 cm in diameter, corresponding to approximate tumor volumes of 0.2 cc-5.0 cc. This leads to optimal localization of pathologically confined cancer for diagnosis. A volume obtained by height, width, and length measurements also provides correla tion with PSA.16
Staging
The confirmation of transrectal ultrasound abnormali ties have been simplified by transrectal automated 18 gauge biopsy. As cancers enlarge, their margins may be come more ill-defined yet also cause adjacent architec tural distortions by mass effect. Capsular bulging, espe cially near the periphery, should prompt closer evalua tion of potential extracapsular extensions. Biopsy of extracapsular extension or adjacent seminal vesicles could produce histologic confirmation, not afforded by other staging modalities. The estimated tumor volume, or gland involvement, has also been suggested by the number of involved cores if systematic biopsy is per formed.17 Systematic biopsy may increase cancer yield, especially in patients with disproportionate PSA eleva tions (e.g. serum PSA > gland vol X 0.1 n g /m l/ cc). PSA density also correlates with increasing probability for extracapsular extension.16,18
Pelvic Lymph Node Dissection
The committee noted that while pelvic lymph node dis section provided the most accurate means of assessing the pelvic lymph nodes, that it was not curative and the recurrence rates reported ranged from 23 to 30%. 19~21 There is a group of patients in whom pelvic lymph node dissection may be of limited benefit as the current inci dence of positive nodes is <5%.
Computed Tomography Scan Magnetic Resonance Imaging
Computed tomography scan magnetic resonance im aging was agreed to provide limited usefulness in stag ing.
Cystoscopy
It was agreed that cytoscopy provides no usefulness in staging.
Radionuclide Bone Scan
Radionuclide bone scan is useful in assessing the bony extent of metastases. It is, however, rarely positive in patients with a serum PSA less than 20 ng/ml. In the absence of an elevated alkaline phosphatase or symp toms, it could be omitted in patients with clinically lo calized cancer, a serum PSA less than 20 ng/ml, and well to moderately differentiated (Gleason 2-7) can- 22 cer.
Pathologic Predictors
In addition to the above-mentioned staging techniques, there are certain pathologic predictors of stage, includ ing Gleason sum and tumor volume, that should be in corporated into the staging algorithm.
Conclusions
The committees agreed that screening may provide a significant impact upon the natural history of prostatic adenocarcinoma, but that the parameters should be well defined. Patients who undergo screening should do so only if they are expected to benefit from the alter ation in therapy. This would include those men 1) in whom prostatic cancer is likely (over the age of 40 or 50), 2) who have an expectation of survival of 10 years or longer and, 3) who are otherwise candidates for ther apy. There are current guidelines by the American Urologic Association and American Cancer Society as to when screening should begin, but these organizations specify no upper limits of age or health at which time screening becomes of little value.
The groups further agreed that the methodology for screening should be a combination of PSA and digital rectal examination. Transrectal ultrasound was felt to be a useful adjunct in the event of an abnormal exami nation. The frequency of examination was discussed, and although the general feeling was that annual exam inations are optimal, there were no data presented to support this stance. The level of " abnormal" PSA should be sufficiently low to allow optimal detection in terms of both numbers of significant tumors and curable tumors (defined as tumors confined to the prostate). This would correlate with a "window of opportunity" between a serum PSA of 2 and 6 ng/m l. Age-specific ranges were discussed and felt to be another attempt to increase the specificity and sensitivity of PSA, yet per sonal data of LaBrie refuted age-specific PSA. 23 Staging systems were discussed and it was felt that because the stage was a reflection of the biologic hazard of the disease, the palpability of a lesion was a poor marker, as a large number of tumors were anterior or hidden in a large adenomatous gland. The best predic tor of biologic hazard is the volume of the tumor, yet there currently is no technology available to accurately assess the volume preoperatively.
M.D., Centro Medico de Urología y Andrologia, Ma laga, Spain; E. Varenhorst, M.D., Department of Sur gery/Urology, County Hospital, Norrkoping, Sweden.
LABORATORY EVALUATION WORKGROUP
It is now well established that the determination of the concentration of prostate specific antigen (PSA) in se rum is of clinical value in monitoring the treatment of patients with prostatic cancer.1 Moreover, there is now good evidence2 that the determination of serum PSA levels will make a significant contribution to the new screening initiatives directed to the recognition of early prostate cancer, Such screening studies are currently the center of considerable controversy,3 although a number of case control studies have established the potential of the serum PSA analysis and digital rectal examination as the currently available primary tests to identify early, probably organ-confined prostatic cancer. Transrectal ultrasonography is generally seen as the secondary pro cedure to be undertaken if either of the primary tests is positive.
Randomized screening studies are necessary to de termine whether the use of such tests is appropriate and when used in populations of asymptomatic normal men, will reduce the mortality from prostate cancer. A range of serum PSA concentrations from 0 to 4.0 ng/m l has been seen for some time by the international uro logic community as normal. Levels of serum PSA greater than 4.0 ng/m l therefore would be viewed with some suspicion with regard to the possibility of cancer, In a population of normal men older than 55 years, 2 to 3% would be expected to have levels of serum PSA greater than 10.0 ng/m l and about 10% would be in the 4.0-10.0 ng/m l range. A valué of 10,0 ng/m l or greater should require serious clinical evaluation, with a large proportion of such subjects expected to have dissemi nated disease. On the basis of such studies, the Ameri can Cancer Society has recommended an annual digital rectal examination and PSA analysis for all men over the age of 50.
The arbitrary PSA value of 4,0 n g /m as a cutoff point for cancer dominated discussion related to screen ing for the last 5 years, with studies indicating that many men in the 4.0 to 10 ng/m l range have cancer confined to the prostate, Considerable emphasis is di rected to the potential value of PSA analysis for the rec ognition of early cancer. Laboratory specialists have in dicated, however, that PSA immunoassays can only provide a guideline as to the level of PSA in serum. 4 There is no internationally recognized PSA standard reference material against which the calibration of such immunoassays for PSA measurement can be validated. There is, moreover, no recognized procedure that would readily be accepted as the "definitive" assay. Different studies have shown the various immunoassay kits for the measurement of PSA, produced by a num ber of diagnostic companies, provided widely varying results from the same serum sample.
The consensus committee discussed the biochemis try relating to the production of PSA by the epithelial cells of the prostate. It is recognized5 that the PSA mol ecule was essentially of the kallikrein family and as a serine proteinase, has the capacity to bind in the serum to the proteinase inhibitors «i-antichymotrypsin and a 2-macroglobulin. 6 A major proportion (65-90%) of the PSA that is measured by PSA immunoassays is in the form of the PSA-c^-antichymotrypsin complex. The PSA that is complexed with a:2-macroglobulin is not recognized by the antibodies currently used as compo nents of any diagnostic PSA immunoassay kit.6"8
The PSA immunoassay kits therefore measure PSA that is in the free, unbound state, and also the PSA that is complexed to -«i-antichymotrypsin. The sum of both indices provides the "total PSA" level in serum,7 De pending on the antibody composition of the various kits, the total PSA value will vary according to whether the free PSA and complexed PSA are determined on an equimolar basis. 9 The experimental data suggest that few commercially available assays can measure free and complexed PSA in an almost equimolar equiva lence pattern. The level of total PSA in serum, measured by procedures that determine the free and the com plexed PSA on an equimolar basis, would be consid ered, at present, to provide the most likely accurate value. The Hybritech Tandem R assay was recognized by the committee as an acceptable provisional reference method. Many other kits do not appear to measure se rum PSA components in this equimolar manner. The committee considered, therefore, that the varying levels obtained with different kits is a problem that could well relate to the capacity of the immunoassay under the specified analytical conditions, to measure free and complexed PSA.
Information was made available to the committee to indicate that when specific assays were established to separately determine the concentration of free PSA as well as the levels of PSA complexed to a r antichymotrypsin, the ratios of free PSA/total serum PSA, or of PSA-^-antichymotrypsin complex/total serum PSA, appear to provide sensitive parameters that would al low a more specific differentiation of patients with be nign prostatic hyperplasia from those with cancer in the screening programs.8,10,11 Such assays could reduce the false positive rate by about 50%.10 It was noted by the committee, however, that these assays are not yet avail able for current screening studies.
The committee considered that it should be prag matic about the "laboratory requirements" necessary for the support of the screening studies and recom mended that a short term and a longer term program should be established. The long term goal is to establish international PSA standard preparations, but in the short term, it will be necessary to prepare a provisional PSA standard that would be available for the Pan-Eu ropean Screening Program. Such a standard could be obtained as follows. First, samples of PSA isolated from seminal plasma should be obtained from sources that could provide evidence of acceptable purity and characterization. A PSA concen tration would then be assigned to the preparation of PSA in buffer medium, by use of "the provisional refer ence assay." Samples would then be aliquoted into tubes for stability experiments, storing samples at vary ing temperatures, from 0°C down to minus 70°C, as a preliminary study to establish conditions for the storage of the European reference materials. A series of labora tories involved with the screening studies would per form the analytical work to assign the PSA concentra tion to the standard preparation. Furthermore, a series of "pools" of serum would be prepared containing lev els of PSA in the range between 0 to 10 ng/ml. These pools would form the basis of a quality assurance pro gram to monitor the performance of the laboratories in volved in the determination of serum PSA for the screening studies. Randomly selected samples of different pools would be dispatched from a designated center to the laboratories at regular intervals and results reported to the quality assessment coordinator.
The committee also accepted that the laboratories would probably require an automated analytical system for the determination of PSA. Although the correlation was seen10 to be excellent, but with a small negative bias, between data generated by the current Abbot IMX automated assay and the Hybritech Tandem R proce dure from the analysis of a series of serum samples, ev idence provided to the committee indicated that there may still be differences between the assays as to how well they measure the free PSA and complexed PSA on a molar equivalent basis. Such differences could be readily overcome by the selection of appropriate anti bodies that can provide equivalence in the detection of different molecular forms of PSA in automated assay systems, although these may not yet be commercially available. It was recommended that if possible, all the laboratories concerned in the screening studies would use an automated assay.
Once evidence that other immunoassay systems were able to provide analytical equivalence and satis factory precision, as documented by the quality assur ance program, then they should be considered for use in the screening studies.
In the longer term, the application to the European Community for financial support for the cooperating laboratories to produce European reference materials containing PSA and PSA-c^-antichymotrypsin com plex would be submitted on April 14, 1994 , the next acceptable date for such requests. Standardized isola tion and characterization procedures would be estab lished and such materials would be processed according to the standards of the European Community Bureau of Reference Materials, to produce the European standard preparations of both PSA and PSA-complex that could then be used for assay validation. It would be expected that diagnostic kits for total serum PSA analysis would determine the different molecular forms of PSA at mo lar equivalence. The complexed PSA would be made available for the development, establishment, and vali dation of the next generation of more specific assays for the determination of the free PSA, and the PSA-a^-antichy mo trypsin complex in serum. The European stan dard preparations would then be made available and distributed through the World Health Organization, if this was considered appropriate.
Although new markers for prostatic cancer will in evitably be developed for future years, a shorter-term goal is to establish the more specific assays for the mea surement of the various molecular forms of PSA. At present, the determination of "total PSA" levels in se rum provides the only practical and rational means available for the identification of early prostate cancer. These assays must be better monitored in the screening studies and assay precision established for the lower 0 to 10 ng/m l range to determine, more accurately, the relevance of the "cancer cut-off point," be it 3.0 or 4.0 ng PSA/ml serum.
TREATMENT WORKGROUP
Introduction
Localized prostate cancer represents a disease spectrum of clinical stages from Tla to T3. Within each stage exist variations in malignant potential. Several clinical, bio chemical, and radiographic factors are considered in the assessment of the individual T stage, including digital rectal examination, transrectal ultrasound, prostate spe cific antigen (PSA), PSA density, magnetic resonance imaging, tumor grade, ploidy, and lymph node status. For example, category T3 includes both patients with minimal capsular penetration (as identified by digital rectal examination, transrectal ultrasound, or even nee dle biopsy) as well as patients who have bulky T3 tu mors with symptoms of an obstructive nature. Some of the former may still be localized and curable, whereas the majority of the latter will have nodal metastases. Despite the importance of T-staging, in some surgical series only 22% of patients have been staged accu rately.1,2
The concept of "localized disease" implies that it is curable, with acceptable treatment mortality. There fore, for the purpose of this workshop discussion, our definition encompasses a range of prognostic criteria that, for an individual patient, are considered to be syn onymous with curability. Many parameters are used to assess curability; for example, a poorly differentiated Gleason sum grade 10 T2 cancer is not likely to be cured, whereas a well differentiated Gleason grade 4 tumor is.
We are witnessing both a stage and intrastage mi gration in prostate cancer toward more favorable prog nostic groups. This phenomenon may influence treat ment selection and must be recognized when at tempting to compare current treatment strategies with past experience.
The presence or absence of lymph node metastasis is an important prognostic factor. When considering treatment for localized disease, lymph node status should be ascertained with reasonable certainty. De spite this, many patients do not undergo lymph nodal assessment. In general, a relationship exists between tu mor (Gleason) grade, PSA, and lymph node status.1,3,4 ( Tables 1 and 2 ) Patients with a PSA less than 20 ng/ml and a Gleason grade less than 7 have a low risk of lymph nodal metastases, However, a poorly differen tiated (Gleason sum 8) with PSA of 15 ng/m l may have a 20% risk of nodal disease. The goal of any treatment for localized prostate cancer is to improve patient sur vival while preserving the best quality of life. In other words, giving the patient "the best chance of dying of something else/' Thus, treatment should be considered for any man with prostate cancer whose survival, in the opinion of the clinician, will be shortened by the cancer. Usually, these are men with a life expectancy greater than 10 years and whose treatment would be expected to influence outcome. In this decade, economic issues as well as therapeutic efficacy are influencing such treat ment decisions. Economically, curative treatment of early disease may be more attractive than treating ad vanced disease. However, it is not known what strategy is ethically and economically desirable.
Treatment Options
Having defined localized prostate cancer and whom to treat, we review the options available for treatment. The choice of therapy depends upon the T stage and, as pre viously discussed, the overall health of the patient. Watchful waiting may be very appropriate for an asymptomatic patient with a Tin cancer whereas a high grade, Gleason 9 T3 cancer may benefit from radiation therapy, even though the likelihood of cure could be remote. Treatment options should be discussed with the patient and in some cases second opinions sought from multiple specialties. Treatment options for localized prostate cancer have been embraced with varying degrees of enthusi asm. Opinions and practices have changed considera bly over the past decade. The list of therapeutic options includes time-honored methods of radical prostatec tomy or radiation therapy as well as watchful waiting, br achy therapy, hormone manipulation, and cryother apy. The major challenge facing the clinician regarding treatment options is the lack of data from randomized clinical trials.
Radical Prostatectomy
Radical prostatectomy is the gold standard for the treat ment of localized prostate cancer. Through the early 1960s, the perineal surgical approach was the only cu rative procedure for highly selected patients with small nodules. As a result of greater understanding of the rel evant anatomy and the refinement of the nerve-sparing retropubic radical prostatectomy, the complications of surgical treatment have decreased significantly.
The most important and significant early complica tion is postoperative mortality. In the age and health group of a screened population, the expected mortality in major centers will be approximately 1% (±0.9%) within 30 days and 1,2% within four months.5"7 In some urologie practices, mortality rates are higher. A second early complication is rectal injury, with a re ported frequency of approximately 3%.8 This complica tion, however, has little long term importance. Stric tures, incontinence, and impotence are the major late complications. None influence survival but all definitely affect quality of life. Stricture frequency is about 20% and relatively easy to handle. Incontinence and impo tence are also age-and stage-related. Overall final in continence rates should be less than 5%, although this is certainly a question of definition. Impotence is a ma jor quality of life issue, but its frequency has decreased considerably with the adoption of nerve-sparing surgi cal techniques.7 Treatment of incontinence and impo tence can have considerable cost implications. These should be taken into account when performing finan cial cost-benefit analysis of screening programs. 8 Perhaps for more than any other treatment mod ality, the outcome of radical prostatectomy is inextrica bly related to pathologic stage. If the malignancy is organ-confined, long term survival is indistinguishable from age-matched m en without prostate cancer.1,6 Fif teen-year survival rates in excess of 50% have been re ported. The survival of men with locally advanced (T3 or T4) disease is considerably less.
The postoperative follow-up of men treated with radical prostatectomy has been revolutionized by the advent of assays for the detection of serum PSA. Mea surable levels of PSA after radical prostatectomy are a harbinger of clinically evident persistence disease, al though the prognostic value of this biochemical marker is unknown with respect to individual morbidity or can cer-specific mortality. The impact of adjuvant therapy on incomplete surgical resection or postoperatively de tectable serum PSA is unknown. Several trials have been initiated to study these issues. At the present time, there is insufficient data to support the use of postoper ative hormone therapy as an adjuvant in the treatment of localized prostate cancer except in the context of clin ical trials.
Neoadjuvant Hormone Therapy
Several studies are in progress evaluating neoadjuvant hormone ablation before radical prostatectomy or radi ation therapy. 2,9"11 Labrie and others2 demonstrated a significant reduction of positive margins in men receiv ing three months of an antiandrogen plus luteinizing hormone-releasing hormone agonist before radical prostatectomy compared with men undergoing imme diate surgery without hormone therapy. Similarly, the Canadian Anadron Trial and the Radiation Therapy Oncology Group have reported significant decrease in local recurrence and improvement in disease free sur vival in men with T3 prostate cancer receiving neoadju vant hormone ablation.11
Cryotherapy
There has been a resurgence of interest in cryoablation owing to improved delivery systems and, particularly, to the ability to visualize tissue freezing by transrectal ultrasound. These factors have contributed to a signifi cant reduction in morbidity. Long term outcome data are lacking, but in one recent series, 62% of men had negative biopsy at three months.12 The ability to freeze beyond to the prostate capsule makes this modality ap pealing for some patients with clinical stage T3 disease. In addition, this approach holds promise for some pa tients failing primary radiotherapy, Morbidity does occur with this method of treat ment. Rectal fistula, sloughing of urethral tissue, impo tence, penile edema, and voiding difficulty have all been reported,12 Long term follow-up of patients un dergoing cryoablation will be required before the effi cacy and morbidity of this procedure can be deter mined. At the present time, this treatment should only be used in the context of a clinical trial.
Radiotherapy
Radical external beam radiotherapy has become possi ble with the development of high energy radiation equipment, earlier with cobalt 60 treatment units and with linear accelerators beginning in the 1960s. The pattern of care study (PCS)13 reported radiotherapy treatment results for localized prostate cancer from a large number of research and nonresearch centers. The aim of this review was to produce data that were un likely to be biased by any single institution. Sixteenyear overall survival of TtN0 patients was similar to a healthy age-matched population. Survival of T2NP was 22% lower than the age-matched controls. Survival of T3/T 4Nq was about 15% lower than T2N0 at 10 years but was identical at 16 years. Other single institution series report essentially similar results.14,15 Pooled data from the literature report 0.2% fatal complications after radiotherapy. The overall incidence of significant uri nary or rectosigmoid sequelae is approximately 3% and 7-10% for severe and moderate complications, respec tively. The most frequent urinary sequelae are radiation cystitis with intermittent hematuria and urethral stric tures. The incidence of severe anal/rectal injury requir ing colostomy is less than 1%. These complications are related to treatment technique. A sexual dysfunction has been described in 14 to 50% for patients depending upon age, time of assessment, and technique of irradia tion. However, prospective data comparing postradio therapy impotence with the natural evolution of sexual dysfunction are presently lacking.14 Progress in radiation computer technology (either with conventional radiation or proton beams) and im aging as well as in the physics of radiation have modi fied the practice of radiotherapy considerably, Emerg ing data for three-dimensional conformal radiotherapy indicate that higher doses can be delivered safely to the prostate gland without increasing treatment morbid ity. 16, 17 This observation assumes particular importance in view of the strong relationship existing between ra diation dose, local control, and survival. 15 The same ra tionale supports the renewed interest in prostate cancer brachytherapy18 although the consensus of this work shop is that the technical difficulties of brachytherapy may limit its role and make it less attractive than 3-D conformal radiotherapy. Long term data on local con trol and survival of localized prostate cancer with these sophisticated modern imaging therapies are not yet available.
Recent data indicate that pretreatment PSA levels, when considered together with clinical stage and grade, will help to define patient subgroups with different probabilities of local control and disease free survival after radiotherapy. Poor prognostic groups on which to focus clinical trials that employ more intensive local treatment or adjuvant systemic therapy including hor mones can be identified by these means. There are also indications that postradiotherapy PSA levels will help to identify at an early stage those patients who are likely to relapse and who should be considered for salvage therapy.19,20
Treatment of Tumor Relapse
Many men treated for localized prostate cancer will demonstrate local recurrence despite the curative intent of the treatment. Recurrence may be identified by sev eral parameters, including palpable local recurrence, positive biopsy, detectable serum PSA after radical prostatectomy, or rising PSA after achieving a nadir in men treated with other modalities. The therapeutic op tions for tumor relapse are predicated on the primary therapy administered. Radiation therapy may be offered to a patient who develops local relapse after radical prostatectomy. The benefit of such treatment is presently unknown. Salvage prostatectomy after radio therapy failure is feasible but rarely successful. Hor mone therapy is usually effective in altering biochemi cal markers (PSA); however, its impact on altering sur vival is unknown. Recently, cryotherapy has been suggested as an alternative for patients failing radiation.
Watchful Waiting
Several studies have provided long term follow-up for watchful waiting of localized prostate cancer indicating a favorable outcome.21"24 These studies have been criti cized for various biases, but their overall conclusion should not be ignored. For many patients with signifi cant comorbidity, watchful waiting may be appropriate because the probability of noncancer death could be high.
The question that remains is whether watchful waiting is equivalent to immediate treatment for healthy patients with a long life expectancy. Four im portant factors raised by these studies need to be con sidered:
Death from Prostate Cancer
These studies reported that death from prostate cancer within 10 years was 7 to 8.5%, compared with 31 to 47% from other causes. Longer follow-up data are lack ing, This survival differential may change, suggesting that the present data should be applied to younger men with caution,
Progression
In most patients, once progression has been observed, cure is no longer possible. One exception is that pro gression from Tlc to T2 may still be curable. Local pro gression to T3 occurred in 22 to 55% of patients, but this causes concern to the physician more frequently than the patient. Patients who need treatment for local pro gression are usually few. Distant metastases developed in 12 to 14 % during watchful waiting. At this time treat ment can only be palliative.
Quality of Life
Assessment of quality of life in patients with localized prostate cancer must be evaluated in terms of "health" rather than "disease/' Although the review by Fleming and others23 was based on such a conception, it did not address the patient's own perception of living with can cer.
T reatment Decisions
Watchful waiting implies treatment for progression. If palliative treatment only is planned, it may be argued that follow-up is not necessary. However, if immediate treatment is considered necessary at the time of pro gression, therapy will depend upon the type of progres sion. Should a rising PSA be treated? If so, at what PSA level? Furthermore, what constitutes "local progres sion?"
Summary
There are advantages and disadvantages to each of the treatment modalities available for localized prostate cancer. For individual patients, treatment selection should consider all these factors in concert with the pa tient's acceptance of the side effects and the expected results of each treatment choice.
Readers should note the absence of a table compar ing the outcome of different treatments, This is not an oversight but illustrates the workshop view that ade quate randomized trials of treatment for localized pros tate cancer have not been performed and that data de riving from different treatment modalities are not com parable. The most pressing issue for the treatment of localized prostate cancer is the development of reliable prognostic markers that will allow the separation of those men who will die of prostate cancer from those who will not. Thereafter, the impact of intervention must be determined.
Meanwhile, the organization of prospective trials is necessary if informed decisions are to be made in the future. In designing such trials, the endpoints must be identified clearly and must include overall survival, time to progression, and quality of life. For this purpose, the assessment of comparative treatment morbidity re quires refinement for use in clinical trials.
Constant monitoring will be needed, and evalua tion analysis must consider not only the trial itself but also any progress in developing therapeutic methods.
trolled trials for effectiveness evaluation. The commit tee mainly considered questions related to the latter.
What Is the Most Appropriate Design to Study the Effectiveness of Prostate Cancer Screening?
The design must avoid biases caused by selection, lead time, and length. This can be best achieved by a con trolled trial in which an identified study population of sufficient size is randomized into two arms. One is offered screening tests, and the other receives routine health care. Both arms are to be followed up from the date of randomization and total prostate cancer mortal ity recorded. Analysis must be on an "intention to treat" basis.1 Within this basic framework, randomization may precede consent (the target population is the same as the study population) or follow consent (the study population is smaller than the target population). If there are ethical objections because the control arm re ceives no potential benefit, then it would be possible to offer screening to the control group after a delay of sev eral years,2,3
Lessons from breast cancer screening trials show that individual randomization is to be preferred.4
Details Concerning Randomized Controlled Screening Trials
Age Range
The selection of the age group is influenced by the inci dence rates and by life expectancy.5 Therefore the com mittee recommended selecting a target group ages 55 to 70 years at entry to the trial. There are no good argu ments for starting screening under the age of 50. Al though some individual men between the ages of 50 to 54 years might have most benefit in terms of years of life gained, the costs for each additional year will be extremely high.
Interscreening Interval
Recent results from the Canadian6 and the US ACS-NCDCP7 demonstration screening projects show inter esting results based on annual prostate specific antigen (PSA) tests, obtaining detection rates of greater than 2.0% to 3.0% after 1, 2, and 3 years screening. Con versely, this short time period may not provide enough relevant data on interval cancer cases to investigate the natural history of the disease under study. In addition, annual screening may be less likely to be cost-effective and could probably result in high costs per additional cancer case detected. Therefore the majority of the com mittee recommended a rescreening period of at least 3 years for randomized controlled trials. Supporting this design are the recent results from the Canadian project.6 Reports from the American Cancer Society Project in the USA support the cost-effectiveness of annual screening.7,8
Screening Tests
Despite evidence that PSA, or PSA combined with DRE, as primary screening tests, could be an effective choice, the use of the 3 screening tests (digital rectal ex amination, PSA, and TRUS) is recommended at the start of the European trial.8-10 At present time there is not enough information available from the European pilot studies to delete one of them as being of poor costeffectiveness for the detection of early cancer cases when a rescreening interval of more than 3 years is pro posed. For scientific purposes it is recommended that serum samples are taken from each individual and stored. Strict objective criteria that could be easily ap plied should be defined for the selection of suspected cases on DRE and TRUS. Biopsy should be taken from patients with suspected cases as agreed by the diagnos tic and laboratory committees.
Outcome Measures
The primary outcome measure of the trial will be pros tate cancer mortality reduction. Quality of life measure ments and cost parameters must also be included as in trinsic components of this trial design. To measure costeffectiveness of different screening strategies and costs per prostate cancer death avoided, it is recommended that resource use in both arms is recorded. The data can be collected for the total group or in a subsample of in dividuals.
Whether analyzing duration of survival, quality of life, or cost parameters, all measurements should be stratified retrospectively for important prognostic fac tors, such as advanced disease.
W hat about Recruitment?
European pilot studies in Rotterdam and Antwerp show that between 36 and 42% of men from the target popu lation are willing to join the study population of ran domized screening trial. Fortunately, screening trials with low rates of recruitment could yield unbiased re sults so long as randomization is applied after recruit ment. High compliance rates within both arms of this study population will increase statistical power. Possi ble specific ways to increase those rates could be the use of professional media techniques and personal mail ings.1 Generalization of the results to the target popula tion will be more straightforward if high recruitment rates have been achieved (or if the study population is representative of the target population). However, pro motion of screening is very complex because it may en hance contamination of the control arm by the use of screening tests. In screening demonstration projects such as conducted in the US, (ACS-NPCDP)7 higher re cruitment rates may be achieved because the message to the population promises potential benefits. This is difficult to promote in the context of a randomized con trolled trial.
Is Overdiagnosis a Concern?
The term "overdiagnosis" refers to the possibility that screening detects excess numbers of small volume (0.05 to 1.00 ml) tumors. Evidence is accumulating in the lit erature that PSA screening, even when accompanied by an aggressive biopsy policy, does not lead to overdi agnosis in this sense.11,12 Overdiagnosis can also be in terpreted as detection and treatment of tumors which, although classified as biologically important, would not have become life threatening. Epidemiologic data on in cidence and mortality of prostate cancer, particularly from the US, show that despite a tremendous incidence increase during the last decade, mortality has remained relatively constant.13 This suggests that screening may lead to overdiagnosis in this latter sense. It could also mean that current screening is finding significant can cers, preventing an increase in mortality despite an in crease in incidence. It will be essential to monitor cumu lative incidence of prostate cancer in the two arms of the trial to determine whatever occurs.
Trial Committees
Several trial committees are required: the causes of death committee, quality control committee, and an in dependent data monitoring committee that will estab lish stopping rules, apply ethical standards to interim results, and if necessary, review early mortality results.
